Angiogenesis, the formation of new blood vessels, is required for normal tissue development and pathological conditions such as tumorigenesis. Most solid tumors can not grow beyond a few millimeters without the recruitment of neovessels since cancer cells require access to blood vessels for nutrients and to escape the local environment and metastasize to other tissue and organ sites. Targeting tumor vessel endothelium therefore should serve as an effective therapy for cancers. Maspin is a serpin that exhibits antiangiogenic properties. In this report, we show that when maspin overexpression is targeted in vivo to endothelial cells, it actively induces endothelial cell apoptosis. Intravascular administration of adenovirusmaspin to mice bearing mammary tumors disrupts tumor-induced angiogenesis. Interestingly, tumor neovessels become leaky after maspin treatment, whereas normal mature vessels are not affected by maspin treatment. We further demonstrate that maspin directly induces endothelial cell apoptosis in vitro, and this effect is maspin specific. The induction of apoptosis is accompanied by changes in the expression of Bcl-2 family genes and is blocked by caspase inhibitors. In addition, the apoptotic effect is mediated by intracellular maspin and is dependent on the RSL region of maspin. Furthermore, we have shown that transient overexpression of Bcl-2 protected the HUVECs from maspin-mediated apoptosis, and the presence of both maspin and Bax accelerated the apoptosis process. These findings demonstrate that neovascular endothelial cells are highly sensitive to maspin level inside the cells. This property can be used for targeted therapy against tumor angiogenesis and metastasis.
Introduction
Angiogenesis, the formation of new blood vessels, is required for normal embryonic development and wound healing (Risau, 1997) . It is also required during pathological conditions, such as cancer (Folkman, 1986; Fidler and Ellis, 1994) . Most solid tumors cannot grow beyond a few millimeters without neovascularization. The new vessels enable the cancer cells to have access to nutrients in the blood stream and also serve as an avenue for cancer cells to escape their local environment and metastasize to other tissue and organ sites. Studies from animal models and clinical experiments have shown a close correlation between the density of tumor vessels and a negative prognosis with respect to tumor invasiveness and metastasis. As tumor cells can easily adapt to and develop resistance to drug treatment, it is widely believed that targeting the tumor endothelium will be a more effective therapy for cancer.
Maspin is a member of the serpin (serine protease inhibitor) family, which exhibits a tumor suppressing function (Zou et al., 1994) . Initially isolated from normal mammary epithelial cells, the maspin gene is not mutated nor deleted in breast cancer, but rather transcriptionally downregulated or silenced by epigenetic alterations (Zhang et al., 1997a, b; Futscher et al., 2002) . Maspin protein made in Escherichia coli, yeast or insect cells inhibits breast tumor cell migration and invasion . In vivo, maspin has been shown to inhibit mammary tumor progression and metastasis. In addition, we have demonstrated that maspin has the ability to inhibit angiogenesis (Zhang et al., 2000b) . Maspin inhibited endothelial cell migration towards basic fibroblast growth factor (bFGF) and VEGF. In a rat cornea pocket assay, maspin was able to inhibit neovascularization. Recently, Cher et al. (2003) have shown that maspin inhibits vasculature density in a prostate xenograft model.
In this report, we present in vivo evidence that when maspin overexpression is targeted to endothelial cells, it actively induces endothelial cell apoptosis. Intravascular administration of adenovirus-maspin (Ad-Mp) to mice bearing mammary tumors disrupts tumor-induced angiogenesis. Tumor neovessels become leaky after maspin treatment, while normal mature vessels are not affected by maspin treatment. We further demonstrate, in vitro, that maspin directly induces endothelial cell apoptosis, and this effect is maspin specific. The induction of apoptosis is accompanied by changes in the expression of Bcl-2 family genes and is blocked by caspase inhibitors. Deletion of the RSL region of maspin abolishes the apoptotic activity. This finding reveals a new mechanism by which maspin inhibits angiogenesis and metastasis.
Results
Previously, we have shown that targeting maspin for cancer therapy effectively blocks breast tumor growth and metastasis (Zhang et al., 2000a; Shi et al., 2002) , and that maspin inhibits tumor angiogenesis in a xenograft model (Zhang et al., 2000b) . We hypothesized that the tumor suppression effect may arise from direct or indirect (paracrine) action of maspin on tumor vascular endothelial cells. To understand the mechanism of maspin action on vascular endothelial cells, we made an Ad-Mp construct, which could target maspin expression to both nonproliferating, mature endothelial cells as well as to the neovascular endothelial cells in tumors. To confirm the functionality of the Ad-MpAdMp preparation, Ad-Mp was used to infect human breast cancer MDA435 cells. The migration rates of cells that were infected with Ad-Mp and control adenovirus (Ad-cont) were compared using a Boyden chamber assay. Ad-Mp infected cells exhibited a significantly reduced migration rate as compared with Ad-cont infected cells, indicating that functional maspin was being produced in the Ad-Mp infected cells (data not shown). To test the effect of Ad-Mp on endothelial cells in tumor vasculature, we implanted TM40D mouse mammary tumor cells to the mammary glands of syngeneic BALB/c mice to generate mammary tumors. TM40D tumors developed in about 4 weeks and were allowed to grow to a size of 0.4-0.6 cm in diameter. Tumors at this size have a luxuriant vasculature but little necrosis (Zhang et al., unpublished observation) . At this point, Ad-Mp or Ad-cont (1 Â 10 11 pfu) was delivered intravascularly through left cardiac ventricle injection to two groups of animals along with Ad-lacZ (1/10 of the concentration of Ad-Mp or Ad-cont) to mark the adenovirus-infected cells. At 2 days after adenovirus delivery, the primary tumors and other tissues were biopsied for histological analysis and immunohistochemistry. Control (Ad-cont treated) tumors had well-organized vessels as indicated by X-gal staining and by Hematoxylin and eosin (H&E) histological analysis (Figure 1a and b) . However, Ad-Mp treated tumors showed disrupted neovasculatures, which was accompanied by vascular leakage of red blood cells (Figure 1c and d) . The X-gal positive vessel structures were confirmed by immunostaining using an antibody against CD31 (data not shown). To quantitate the blood vessel leakage in Ad-Mp treated tumors, fresh tumor samples were harvested and levels of hemoglobin protein were assayed. Vascular leakage results in an increased release of hemoglobin protein from vessels to tumor tissues. As shown in Figure 1e , Ad-Mp treated tumors had a significantly higher level of hemoglobin than Ad-cont treated tumors. Interestingly, large and mature vessels in mammary gland and kidney maintained the intact vessel structure following a short-term treatment of Ad-Mp and AdlacZ (data not shown). A previous report showed that a long-term delivery of maspin expression vector by liposome did not cause an adverse effect on vasculatures in mice (Shi et al., 2002) . Since adenovirus is delivered through circulation, it is expected that endothelial cells would be the major type of cells targeted by adenovirus. The fact that we observed an increased vascular leakage in Ad-Mp treated tumors suggests that maspin treatment may cause vascular damage in neovessels within tumors.
The blood vessel leakage induced by maspin could result from the apoptosis of endothelial cells. To determine whether maspin affects endothelial apoptosis, human umbilical vein endothelial cells (HUVECs) were infected with Ad-Mp or Ad-Cont. Immunostaining of Ad-Mp or Ad-cont infected HUVECs with an antimaspin antibody showed strong immunostaining of maspin protein in the cytoplasm of Ad-Mp infected HUVECs but maspin staining was at a low, basal level in Ad-cont treated cells (Figure 2a ). Western blot analysis confirmed the presence of high level of maspin protein after Ad-maspin infection (Figure 2b ). One noticeable effect of Ad-Mp infection was that many AdMp infected HUVECs were either detached from the plate or appeared to be undergoing cell death. We performed TUNEL analysis to confirm endothelial cell death. A large percentage of Ad-Mp infected HUVECs underwent cell death whereas Ad-cont infected HUVECs exhibited a much lower rate of cell death . To further quantitate the difference in the rate of cell death between Ad-Mp and Ad-cont infected cells, we measured the caspase 3 activity of treated HUVECs using a fluorescence assay (Gurtu et al., 1997) . This measurement represents the relative degree of programmed cell death or apoptosis in HUVECs. As shown in Figure 3e , Ad-Mp infected cells exhibited increased caspase 3 activity compared to that of Ad-cont infected cells. There was a dose-dependent response of apoptosis with increased dosage of Ad-Mp, suggesting a specific effect of maspin on endothelial cell apoptosis. Previously, we showed that exogenous maspin inhibited endothelial cell migration. To determine whether maspin-mediated apoptosis in Ad-Mp treated HUVECs is through the action of secreted maspin, we treated HUVECs with recombinant maspin at various dosages. We measured the caspase 3 activity of treated HUVECs using a fluorescence assay (Figure 4a ). Recombinant maspin did not increase HUVEC apoptosis at any of the dosages tested. However, the cell adhesion and migration rate of maspin treated HUVECs were clearly inhibited (data not shown). To prove that maspin specifically induces apoptosis in endothelial cells, we tested the ability of apoptosis induction for PAI-1 and PAI-2, two serpin molecules with high homology to maspin. We treated HUVECs with adenovirus PAI-1 and PAI-2 at the same dosages as used for the Ad-Mp treatment. Treatment of HUVECs with Ad-PAI-1 and Ad-PAI-2 did not cause any induction of apoptosis (Figure 4b ), suggesting that the ability of maspin to induce apoptosis in HUVECs is specific. Since maspin treatment seems to affect tumor neovasculature but not the large vessels, we reasoned that maspin might only induce the apoptosis of proliferating endothelial cells such as those found in the neovessels of tumors. To test this hypothesis, we grew the HUVECs to subconfluence and then withdrew the serum from the medium for 7 days. Most cells grown under this condition were generally in G0, or a nonproliferating stage. In a pilot experiment, we infected both nonproliferating and proliferating HUVECs with Ad-b-gal to determine whether the proliferation status of HUVECs affects the infection rate. Ad-b-gal adenovirus infected the nonproliferating HUVECs as efficiently as the proliferating HUVECs (data not shown).
We then treated these cells with Ad-Mp or Ad-cont and harvested the cells to measure their apoptosis rate using a fluorogenic caspase 3 assay. As shown in Figure 5 , the basal level of caspase 3 activity in nonproliferating HUVECs was significantly lower than that of the proliferating cells. The relative level of caspase 3 in nonproliferating cells was nearly 37% of that of the proliferating HUVECs. The proliferating HUVECs responded to Ad-Mp with increased caspase 3 activity. However, Ad-Mp treated nonproliferating HUVECs had the same low level of caspase 3 activity as that of Ad-cont treated or untreated nonproliferating HUVECs ( Figure 5 ). We also confirmed that there was a very low level of cell death in both Ad-Mp treated and Ad-cont To further determine the specificity of maspin induced endothelial cell apoptosis and the pathway(s) involved in the apoptosis, we first tested the effect of caspase inhibitors in Ad-Mp treated HUVECs. Addition of a specific caspase 9 inhibitor to Ad-Mp treated HUVECs blocked caspase 3 activity in a dose-dependent manner.
A caspase 8 inhibitor also had a similar inhibitory effect ( Figure 6 ). These data suggest that maspin-induced apoptosis in endothelial cells may either involve both the caspase 8 and the caspase 9 pathways or may involve cross talk between caspase 8 and 9 pathways. A recent study shows that activate caspase 8 is directly associated with the mitochondrial membrane during apoptosis, and caspase 3 is cleaved by caspsase 8 in the process (Tang et al., 2000) . The Bcl-2 family of proteins consists of proand antiapoptotic proteins that act through the mitochondria to regulate apoptosis through caspase 9 and the cytochrome c pathway. Since activation of caspase 8 can also affect the mitochondria/cytochrome c pathway either through a cross talk involving a Bcl-2 family member or direct binding to the mitochondrial membrane (Luo et al., 1998; Tang et al., 2000) , we focused our attention on Bcl-2 family proteins and the mitochondrial mediated apoptosis pathway. We examined the protein levels of two key apoptosis pathway components in the HUVECs. These proteins were Bax, a proapoptotic protein (Li et al., 1998) , and the antiapoptotic protein, Bcl-2 (Yang et al., 1997; Li et al., 1998 Li et al., , 2001a . When the cells were treated with the Ad-Mp to induce apoptosis, the level of the antiapoptotic protein, Bcl-2, was consistently lower than that of cells either treated by Ad-cont or untreated control cells. However, levels of the proapoptotic protein, Bax, increased after HUVECs were treated with Ad-Mp ( Figure 7a ). To understand whether the lack of induction of apoptosis in nonproliferating HUVECs by Ad-Mp treatment is due to the inability of maspin to change the Bcl-2/Bax level, we compared the Bcl-2/Bax levels between proliferating HUVECs and nonproliferating HUVECs that were treated with Ad-Mp or Ad-cont. The Bcl-2 level in nonproliferating HUVECs remained stable when cells were treated by either Ad-Mp or Ad-cont. Unlike the proliferating Targeted maspin overexpression does not cause the apoptosis in nonproliferating HUVECs. Nonproliferating HUVECs (dark bars) and proliferating HUVECs (gray bars) were either untreated or infected with 50 MOI Ad-cont or Ad-Mp for 72 h. Cells were harvested for the caspase 3 activity assay. Note the low level of caspase 3 activity in nonproliferating HUVECs that were untreated or treated with either Ad-cont or Ad-Mp Figure 6 Maspin induced apoptosis in HUVECs is inhibited by both caspase 8 and 9 inhibitors. HUVECs were either untreated or infected with Ad-Mp at 100 MOI for 3 days. Caspase inhibitors were added daily at the indicated dosages. Cells were harvested for caspase 3 activity using a fluorogenic caspase 3 assay. Note the dose-dependent inhibition of caspase 3 activity in Ad-Mp treated HUVECs, which were treated by different amounts of caspase 8 and 9 inhibitors HUVECs, the nonproliferating HUVECs did not increase the Bax level after being exposed to Ad-Mp treatment (Figure 7b) .
To observe the maspin-mediated apoptosis process under the microscope, we constructed a maspin-EGFP (Mp-EGFP) fusion expression vector. This construct or an EGFP control vector were transfected into the HUVECs. Using a fluorescence microscope, we observed that Mp-EGFP positive cells were rounded and began to detach from the cell culture plate about 12-24 h after transfection. In contrast, the control EGFP transfected cells exhibited a normal morphology and were nicely attached (data not shown). We compared the number of Mp-EGFP and EGFP-positive cells at 6 and 30 h after transfection. While there was a relatively high number of Mp-EGFP positive cells at 6 h, the numbers decreased dramatically at 30 h after transfection ( Figure 8a ). All Mp-EGFP transfected cells became apoptotic and were eliminated within the first few days after transfection. No Mp-EGFP overexpressing clones could be established after numerous transfections, whereas EGFP vector transfected cells could live and be passed for further culture without any complications (data not shown). This result further confirms that maspin induces endothelial cell apoptosis when it is introduced by either adenovirus infection or transfection. To further confirm at the microscopic level that the effect of maspin is through the Bcl-2/Bax signal axis, we Maspin induces endothelial cell apoptosis Z Li et al transiently transfected the HUVECs with Bcl-2-EGFP, Bax-EGFP, and control EGFP expression vectors. The EGFP-tagged transfectants were then treated with Adcont or Ad-Mp for a period of 24 h. By counting the number of EGFP-positive cells using a fluorescence microscope and comparing the numbers of EGFPpositive cells between 0 and 24 h after various treatments, we concluded that Bcl-2 protected the HUVECs from maspin-mediated apoptosis, and the presence of both maspin and Bax accelerated the apoptosis process (Figure 8b ). To further determine whether a particular region of maspin protein is responsible for maspinmediated apoptosis in HUVECs, two maspin mutant expression constructs were made. One was an N-terminal deletion of 139 amino acid (aa), which resulted in the generation of a truncated maspin from 140 to 375 aa (maspinDN), and the other is a C-terminal deletion from 340 to 375 aa that removed the RSL domain of maspin (maspinDRSL). Expression vectors of maspin, maspinDN, and maspinDRSL were each cotransfected into HUVECs with another expression vector containing neomycin marker. At 5 days after transfection, cells were harvested for the detection of maspin and mutant maspin expression vectors by PCR analysis. As a control, the neomycin marker was detected in all of the transfected cells. However, cells with maspin and maspinDN were not detectable, suggesting that they were selectively eliminated following transfection (Figure 9 ). The maspinDRSL transfectant was consistently detected, suggesting that the deletion of the C-terminal region of RSL renders the maspin nonfunctional for the induction of apoptosis ( Figure 9 ). All three maspin expression constructs could be transfected easily into mammary tumor cells and were detectable either by PCR analysis following transient transfection or by Western blot analysis using cell extracts isolated from the stable transfectants (data not shown). These data indicate that proliferating HUVECs are highly sensitive to maspin expression level, and the RSL region of maspin is involved in the induction of apoptosis in HUVECs.
Discussion
Cancer gene therapy requires an effective delivery system and low toxicity. Previously, we demonstrated that systemic delivery of maspin DNA:liposome by intravascular injection inhibited the growth and metastasis of breast tumors (Shi et al., 2002) . We hypothesized that maspin exerted its effect through vascular endothelial cells since they were the cells that were initially targeted by maspin gene. To prove this hypothesis, we made an adenovirus maspin construct (Ad-Mp) to target maspin to both proliferating neovessels and nonproliferating mature vessels. In this report, we demonstrated that maspin could indeed cause vascular disruption in tumors that were treated with Ad-Mp for a short time period. This disruption leads to the leakage of red blood cells as analysed by histology and by a quantitative assay for hemoglobin. However, maspin acted selectively on neovascular endothelial cells and not on mature vessels. We have compared the vasculature of tissues from other organs with the vasculature of mammary tumors after the mice were treated by AdMp. No maspin-mediated vascular disruption or leakage occurred in other tissues, such as lung and kidney. In adult mice, the normal vascular systems are well developed and there is no neovascular formation unless induced by pathological conditions, such as wound healing or tumorigenesis. In mice bearing mammary tumors, active angiogenesis occurs in order to provide the tumor cells with adequate supply of nutrients. Under this condition, maspin treatment is effective against the neovascular endothelial cells. Such selective action is of benefit for cancer therapy since delivery of maspin to other organs does not exert a toxic effect. A longer exposure to maspin treatment (via intravascular delivery) has been tested in normal mice previously (Shi et al., 2002) . After the delivery of liposome:maspin for twice a week for 8 weeks, no defect was observed in the reproductive function of the mice. In addition, no visible abnormality in other organs was observed in maspin treated mice. This study confirms our previous report. All of these data suggest that extended exposure to maspin is unlikely to cause adverse effect in vivo. Thus, maspin treatment offers an effective, low toxicity therapy option for cancers. An important finding from this study is that maspin directly induces apoptosis of proliferating endothelial cells. We used human HUVECs to test the sensitivity of endothelial cells to maspin treatment. Infection of HUVECs with Ad-Mp caused the cells to undergo apoptosis even when they were growing in high serum Figure 9 Maspin and maspinDN were selectively eliminated in HUVECs transiently transfected with the maspin, maspinDN, and maspinDRSL expression vectors. HUVECs were co-transfected with a neomycin marker and were cultured for 5 days before they were harvested for DNA isolation. Note that maspinDRSL was not eliminated in the transfected cells, and control neomycin was present in all transfected cells. Data shown represented the results obtained from three repeated transfection assays medium. Additionally, we were unable to overexpress maspin in HUVECs suggesting these endothelial cells are extremely sensitive to maspin dosages. Previously, we treated bovine capillary endothelial cells with exogenous maspin (Zhang et al., 2000b) . The maspin treatment also inhibited the growth rate of bovine endothelial cells. Such sensitivity to maspin seems to be unique for endothelial cells since we were able to express maspin in breast tumor cells and establish stable expression clones, although most of them expressed maspin at a relative low level. These maspin expressing tumor cells were also more prone to apoptosis when they were placed under serum-free conditions or in the presence of an apoptosis inducer, as compared with control tumor cells without maspin expression. This could be due to the fact that tumor cells have high survival-related kinase activities and are defective in their apoptosis response. Unlike normal proliferating endothelial cells, which undergo apoptosis in response to stress or survival signals, tumor cells do not undergo apoptosis easily because they have some defects in their ability to activate the death signaling pathway (Hanahan and Weinberg, 2000) . These studies collectively suggest that targeting tumor neovascular endothelial cells with maspin may offer an effective option for cancer therapy.
Previously, we showed that exogenous maspin inhibited endothelial cells migration and angiogenesis in rat corneal and a tumor model (Zhang et al., 2000b) . To determine whether the effect we observed with maspin overexpression is due to the secreted maspin acting on cell surface, we treated HUVECs with recombinant maspin at various dosages as tested in our initial study. These treated cells were then assayed for the apoptosis rate. We did not observe any increased cell death after the treatment of maspin protein at any dosages. However, such treatment did inhibit HUVEC cell migration and increase cell adhesion to both fibronectin and laminin (data not shown). Interestingly, when maspin is overexpressed in breast tumor cells it also induces tumor cell apoptosis. We have recently obtained evidence that such effect is not mediated by extracellular maspin in tumor cells, but through an intracellular event (Manuscript in press). Clearly, extracellular and intracellular maspin acts differently. We believe that under physiological condition, maspin mainly acts on the surface of endothelial cells, while the apoptosis effect by maspin is observed when endothelial cells are targeted for maspin overexpression, such as in the case of tumor treatment by intravascular delivery of maspin. Thus, intracellular and extracellular maspin displays two different modes of action under normal or stressed/ induced condition. Another very important point is that the ability to induce apoptosis in endothelial cells is maspin-specific. Treatment of HUVECs with Ad-PAI-1 and Ad-PAI-2 does not induce any apoptosis (Figure 4b ). Most serpins are found to inhibit apoptosis through their respective antiprotease functions Dickinson et al., 1998; Suminami et al., 2000) . This is because effective control of proteolysis is essential for homeostasis and inhibitory serpins serve to control the activity of proteolysis and therefore are important regulator of apoptosis process. With regard to the location of action, some serpins act on the cell surface. For example, PAI-2 and SCCA-2 are involved in the inhibition of TNF-mediated apoptosis through cell surface interaction (Dickinson et al., 1998; McGettrick et al., 2001) . Other serpins act to inhibit intracellular proteases such as granzyme B and caspases Bird et al., 1998) . The fact that intracellular maspin induces apoptosis is a unique feature among serpins. Furthermore, we show in this study that intracellular maspin depends on different domain in the induction of apoptosis as compared to the extracellular maspin, which acts independent of RSL region. The RSL region of maspin is different from that of other serpins (such as PAI-1 and PAI-2). This may explain why maspin, not other serpins possesses an apoptotic activity.
The fact that the apoptosis in Ad-Mp infected HUVECs was partially blocked by both a caspase 8 inhibitor and a caspase 9 inhibitor is intriguing. Several other reports also show that certain reagents can induce caspase 3 activity and apoptosis through both the activation of caspase 8 and 9 (Gilot et al., 2002; LaVallee et al., 2003; Choi et al., 2004) . For example, it has been demonstrated that caspase 8 is activated. In addition, there are numerous reports demonstrating the cross talk between caspase 8 and 9 (Luo et al., 1998; Deng et al., 2002) . Caspase 8 is frequently activated in response to apoptotic stimuli independent of death receptor involvement (Choi et al., 1998; Juin et al., 1999; Sanchez et al., 1999) , and during these apoptosis processes the caspase 9 is also activated. Two studies showed that caspase 8 activation is dependent on the activation of caspase 9 (Ferrari et al., 1998; Slee et al., 1999) . Moreover, a recent study shows that activate caspase 8 is directly associated with the mitochondrial membrane during apoptosis (Chandra et al., 2004) . Finally, there is also a possibility that the inhibitors used may have crossreactivity in HUVECs.
The observation that maspin treatment causes a change in Bcl-2 family protein suggests that the apoptosis may be mediated by a signal transduction pathway involving the mitochondria and the Bcl-2 protein family (Budihardjo et al., 1999) . This pathway is normally activated under stress and DNA damage or by chemical inducers. Under normal conditions, survival kinases, such as ERKs and AKT, keep death signals in check (Datta et al., 1999) . This can be achieved, for example, by activating the antiapoptotic Bcl-2 protein. However, upon stress or DNA damage activation, proapoptotic proteins and other factors bind to mitochondria to release mitochondrial proteins, such as the cytochrome c protein (Li et al., 2000) . This release can be blocked by Bcl-2. Cytochrome c interacts with the Apaf-1 adaptor, pro-caspase 9, and dATP to form a complex called the apoptosome (Li et al., 1997) . This complex activates caspase 9, which then digests and activates effector caspases to induce apoptosis (Soengas et al., 2001) . Our data indicate that in maspin expressing endothelial cells, the Bcl-2 level was decreased and the level of the proapoptotic protein, Bax, was increased. However, in nonproliferating HUVECs, maspin treatment did not cause any increase of Bax or decrease of Bcl-2, which explains why the vascular structures remain intact in mature, large vessels. A recent study by Liu et al. (2004) showed that maspin also caused an increased expression of Bax in tumor cells. Others showed that Bcl-2 protein was dephosphorylated and was targeted to ubiquitin-dependent degradation during apoptosis in HUVECs (Dimmeler et al., 1999) . Our finding that there is a change of Bcl-2 family proteins in quiescent and proliferating HUVECs is in line with these previous studies. Therefore, we expect that due to the altered levels of Bcl-2 and Bax proteins, the caspase 9 and mitochondrial death pathway become active in maspin-expressing HUVECs and the apoptosis process is induced. Future studies will address the molecular mechanism(s) by which maspin regulates the Bcl-2 family proteins.
In conclusion, we have clearly demonstrated that maspin induces endothelial cell apoptosis. Targeting maspin to the endothelial cells in mammary tumors disrupts neovasculatures and causes vessel leakage. In vitro, maspin overexpressing endothelial cells undergo increased apoptosis, which can be blocked by inhibitors of both caspase 8 and 9. Maspin expressing HUVECs have a lower level of Bcl-2 protein but increased level of Bax protein as compared with control cells. Such maspin action does not affect mature vessels in vivo or nonproliferating endothelial cells in vitro. Our findings offer a new direction for nontoxic cancer therapy since maspin is produced by the cells in vivo and does not exert any adverse effects. Identifying the molecular mechanisms of maspin-mediated apoptosis will aid in the development of maspin-based antiangiogenic therapeutic interventions.
Materials and methods

Adenovirus vectors
The following replication-deficient adenovirus (Ad) vectors were generated in our laboratory: AdCMV. maspin (Ad-Mp), which expresses human maspin; AdCMV.null (Ad-cont), which carries no insert and was used as a control; AdCMV b-gal (Ad-lacZ), which carries the cDNA for E. coli lacZ gene and codes for the enzyme b-galactosidase. All Ad vectors were amplified and titrated in 293 cells and purified.
Animals
All protocols for experiments involving animals were approved by the Animal Research Committee at Baylor College of Medicine. For all surgical procedures, mice were anesthetized by intraperitoneal injection of Avertin (2.5% in saline, 15 ml/g body weight). Female 12-week-old BALB/c mice were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN, USA) and were housed in a pathogen-free environment. Each experiment involved 20 animals.
Implantation of tumor cells to BALB/c mice
The procedure was based on the method described in Shi et al. (2001) , modified as follows. TM40D cells were grown to 70-85% confluence before being harvested for cell counting. Each #4 mammary gland of 12-week old BALB/c mice was injected with 7 Â 10 5 TM40D cells in a volume of 10 ml. Both #4 mammary glands of the same mouse were injected with the same tumor cells. Tumor initiation was monitored every 2 days by palpation. Tumor volume was calculated using the following formula: length Â width 2 /2. Tumor growth rate was monitored every 2 days by caliper measurement and tumor volume wa calculated as volume (mm 3 )/day. All mice uniformly developed palpable tumors by about 4 weeks after tumor implantation. When the tumor size grew to a diameter of 5-10 mm on any axis, they were randomly placed into one of two groups for intracardiac injections of Ad-LacZ and/or Ad-Mp.
Intracardiac injections of Ad-LacZ and/or Ad-Mp in tumorimplanted BALB/c mice
The procedure was based on a method described in Li et al. (2001b) , modified as follows. The mice were placed in a prone position and a 27-guage needle was inserted into the left cardiac ventricle. After drawback of fresh arterial blood was confirmed, 1 Â 10 11 adenovirus particles in 100 ml of phosphatebuffered saline (PBS) were slowly injected into the left cardiac ventricles of the animals. After injection, the mice were placed on a heating pad to recover from anesthesia and then returned to their cages. The mice were killed 48 h postinfusion. The tumor mass in the mammary gland was excised and fixed in 10% formalin. In addition to the tumors, tissues from lung and kidney were also collected. All tissues were embedded in paraffin and sectioned at 5 mm. The slides were serially sectioned for histological analysis by H&E staining, X-gal staining, and immunohistochemistry. For histological analysis, 10 sections from each sample were examined.
X-gal staining
The samples were tested for b-galactosidase activity using an X-gal reagent. The procedure was based on a method described in Yuan et al. (2002) , modified as follows. Briefly, sections were incubated with an X-gal reagent solution containing 5 mmol/l potassium ferricyanide, 5 mmol/l potassium ferrocyanide, 0.2 mmol/l MgCl 2 , 0.1% Triton X-100, and 0.1% 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal, Sigma, St Louis, MO, USA) in PBS (pH 7.8) for 3-6 h or overnight at room temperature (22-251C). Sections were rinsed and counterstained with nuclear fast red. A positive X-gal reaction was indicated by the presence of a blue precipitate in cell nuclei.
Immunohistochemistry
Maspin and CD31 expression was evaluated by immunostaining. Tissue sections were treated with proteinase K (10 mg/ml) for 10 min at 371C and quenched with 0.03% H 2 O 2 in PBS for 30 min at room temperature. The slides were blocked with 5% normal goat serum for 1 h before they were treated with the primary antibody: rabbit anti-maspin, Abs4A, at a dilution of 1 : 200 or rat anti-CD31 (Pharmingen, San Diego, CA, USA) at a dilution of 1 : 25. The slides were rinsed and sections were incubated for 1 h at room temperature with the secondary antibodies: goat anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1 : 400 and goat anti-rat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1 : 75. Slides were then rinsed and incubated with an avidin-biotin-peroxidase complex (VECTASTAIN s ABC kit; Vector Laboratories, Burlingame, CA, USA), followed by 3,3 0 -diaminobenzidine color development (DAB kit; Zymed Laboratories, Inc., South San Francisco, CA, USA). Micrographs were taken with a Leica microscope equipped with a digital camera (Cool Snap) and further processed using Adobe s Photoshop s software.
Hemoglobin assay
The procedure was described previously (Tuxhorn et al., 2002) . The tumor tissues were transferred to microcentrifuge tubes containing 50 ml double-distilled H 2 O and then homogenized with disposable pellet pestles (Fisher Scientific, Fairlawn, NJ, USA). Homogenates were mixed with 0.5 ml Drabkin's solution (Sigma) and incubated for 15 min at room temperature. Samples were centrifuged to pellet cell debris, and the supernatant was filtered through a 0.45 mm filter. The absorbance of the filtered supernatant was measured at 540 nm, with Drabkin's solution used as a blank. The absorption value, which is proportional to total hemoglobin concentration, was normalized to the tumor weight.
Cells and cell culture
TM40D mammary tumor cells were grown in DMEM/F12 medium with 2% fetal bovine serum (FBS), epidermal growth factor, and insulin as described previously (Shi et al., 2001) . HUVECs (Clonetics, San Diego, CA, USA) were cultured in endothelial basal medium (EBM) supplemented with 2% FBS, 12 mg/ml bovine brain extract (BBE), 10 ng/ml human epidermal growth factor (hEGF), 1 mg/ml hydrocortisone, 50 mg/ml gentamicin, and 50 ng/ml amphotericin (all from Clonetics).
Cell culture and infection
HUVECs (5 Â 10 4 /well) were seeded in 24-well plates and cultured in EBM supplemented described as above. At the time of infection the medium was removed, cells were washed with PBS, and overlaid with serum-free EBM containing 0, 25, 50, or 100 p.f.u. AdCMV per cell (MOI) or AdCMV.bgal. After 60 min the infection medium was removed, the cells were washed with PBS and overlaid with fresh growth medium. HUVECs infected with AdCMV.bgal were subjected to X-gal staining as previously described as described above.
Immunostaining for maspin expression in HUVECs after infection
For immunostaining, 5 Â 10 3 cells (HUVEC) were grown on chamber slides and infected as described above with either AdMp or Ad-cont (50 MOI), or were not infected. At 3 days after infection, the cells were fixed in 4% paraformaldehyde solution for 1 h. The slides were blocked with 10% normal horse serum for 1 h before they were treated with the primary antibody, Abs4A, at a dilution of 1 : 200. The secondary antibody (Texas-red conjugated goat anti-rabbit antibody; Santa Cruz Biotechnology) was used at a dilution of 1 : 1000 at room temperature for 1 h. Slides were viewed under a Leica fluorescence microscope.
Western blot analysis
8 Â 10 6 HUVECs were seeded in 100 mm dishes and infected as described above with either Ad-Mp or Ad-cont (50 MOI), or were not infected. At 1, 3, or 5 days after infection, the cells were collected for protein extraction and Western blot analysis. At these time points, the cells were washed with PBS and lysed with lysis buffer: 10 mM Tris-HCl, 1% SDS, 1 mM phenylmethanesulfonyl fluoride (PMSF; Boehringer Mannheim, Mannheim, Germany), and 10 mg/ml aprotinin (Boehringer Mannheim). Cell lysates were centrifuged and protein concentration was determined using the Bradford method (Bio-Rad, Hercules, CA, USA). Proteins were separated on 4-20% trisglycine polyacrylamide gels (Novex, San Diego, CA, USA) and transferred onto nitrocellulose membrane (Novex). The membrane was incubated with a mouse antimaspin antibody that was made in this laboratory followed by incubation with a secondary antibody (horseradish peroxidase-conjugated goat anti-mouse IgG; Boehringer Mannheim). Maspin protein was visualized using an ECL system (Amersham, Arlington Heights, IL, USA). Bax and Bcl-2 protein levels were also detected by incubating membranes with anti-human Bax and anti-Bcl-2 antibodies (BDPharMingen, CA, USA). Levels of tubulin protein were used as an internal control.
Proliferation assay
For the proliferation assay, 1 Â 10 5 HUVECs were seeded in 60-mm dishes and infected as described above with Ad-Mp or Ad-cont (25, 50, or 100 MOI), or were not infected. Subsequently, the infection medium was substituted with standard growth medium, which was changed every 2 days. Cells were harvested 5 days after infection using trypsin/ EDTA and cells were counted with a hemocytometer. All experiments were performed in duplicate.
TUNEL assay
A terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) apoptosis detection kit (Upstate, Waltham, MA, USA) was used for DNA fragmentation fluorescence staining according to the manufacturer's protocol. In brief, 5 Â 10 3 cells were grown on chamber slides and infected as described above with either Ad-Mp or Ad-cont (50 MOI), or were not infected. At 3 days after infection, the cells were fixed in 4% paraformaldehyde solution for 1 h and incubated with a reaction mix containing biotin-dUTP and terminal deoxynucleotidyl transferase for 60 min. Fluoresceinconjugated avidin was applied to the sample and incubated in the dark for 30 min. Positively stained fluorescein labeled cells were visualized and photographed using a Leica fluorescence microscope. Four 200 Â fields were visualized and each with 150-200 cells were counted.
Caspase 3 activity assay 5 Â 10 4 HUVECs (per well) were seeded in 24-well plates. At the time of infection the medium was removed, the cells were washed with PBS and overlaid with serum-free EBM containing 0, 50, or 100 p.f.u. per cell (MOI) of either Ad-Mp, AdCont, Ad-PAI-1, Ad-PAI-2, and serum-free EBM alone. For exogenous maspin treatment, recombinant maspin prepared as described previously (Zhang et al., 2000b) were added to the HUVECs in 24-well plate for 6 h. Cells were harvested for caspase 3 assay. For caspase inhibitor blocking experiment, the caspase 8 inhibitor II (Z-IETD-FMK) or caspase 9 inhibitor II (LEHD-CHO) (Chemicon, CA, USA) were added daily into the media at a concentration of 5 or 20 nM to block the perspective caspase pathways. At 3 days after infection, caspase 3 activity was assayed using a fluorescent peptide substrate, Ac-DEVD-AMC (Chemicon, CA, USA), according to the manufacturer's instruction manual. In brief, cells were treated with lysis buffer (10 mmol/l Tris-HCl, 10 mmol/l NaH 2 PO 4 /NaHPO 4 , pH 7.5, 130 mmol/l NaCl, 1% Triton-X-100, 10 mmol/l sodium pyrophosphate), and lysates were centrifuged at 12 000 g for 15 min. The supernatant was collected, and the protein concentration was measured using the Bradford method (Bio-Rad). Next the lysate, fluorogenic substrate (Ac-DEVD-AMC), and reaction buffer (40 mmol/l HEPES, pH 7.5, 20% glycerol, 4 mmol/l DTT) were mixed in a 96-well microtiter plate (Corning Costar, NY, USA). Cleavage of the substrate was monitored by liberation of 7-amino-4-methylcoumarin (AMC), which was quantitated in a Spectrafluor (SLT Lab Instruments; excitation, 360 nm; emission, 465 nm) at 371C. The fluorescence was measured and caspase activity was normalized to the protein concentration.
Construction and transfection of expression vectors
Constructs containing the mutant GST-fusion proteins, namely maspinDN and maspinDRSL were used for PCR amplification to clone DNA fragments encoding the desired maspin regions into a mammalian expression vector (primers were presented below). Briefly, DNA fragments containing full-length maspin cDNA and the deleted maspin regions (maspinDN and maspinDRSL) were produced by PCR amplification, digested with either EcoRI or XhoI and XbaI, and cloned into a pEF-IRES-Puromycin vector digested with the same pair of enzymes. A control vector is pEF-IRESNeomycin. Maspin and mutant expression vectors were transfected together with the control vector in a ratio of 1 : 1 into the HUVECs by the use of Lipofectamine (Life Technologies) according to the manufacturer's protocol. At 5 days after the transfection, cells were harvested for DNA extraction. The presence of mouse maspin cDNAs and the neomycin control DNA were determined by PCR analysis using the following primers: Maspin (for maspinDRSL and maspin full length); sense: 5 0 -GCTTTTGCTGTTGACTTG TTC-3 0 , antisense: 5 0 -TTGGTGTCTGTCTTGCTGATT-3 0 ; Maspin (maspinDN); sense: 5 0 -GATGGTGGTGAG-3 0 ; antisense: 5 0 -ACAGACAAGTTCCCTGAGA-3 0 ; Neomycin; sense: 5 0 -CAGAAGAACTCGTCAAGAAGG-3 0 ; antisense: 5 0 -CACTGAAGCGGGAAGGGACTG-3 0 . An EGFP expression vector was purchased from Clontech, Inc. (Clontech, Palo Alto, CA, USA). Maspin-EGFP (Mp-EGFP) was constructed by fusing EGFP to the C-terminus of the maspin cDNA (in frame) to generate a fusion protein. Bax-EGFP and Bcl-2-EGFP expression vectors were kindly provided by Dr Youle at NIH. HUVECs were seeded in sixwell plates at 10 000 cells/well. After allowing the cells to adhere, they were transfected with Mp-EGFP, EGFP control vector, Bax-EGFP, or Bcl-2-EGFP expression vectors using Lipofectamine according to the manufacturer's directions (Life Technologies, Inc., Gaithersburg, MD, USA). Briefly, 2 mg of DNA and 12 ml of Lipofectin were combined with 1 ml of medium without serum and added to each well. Cells were incubated for 24 h. Subsequently, fresh medium was added, and the cells were incubated for an additional 24-72 h. The morphology of the cells was visualized and photographed using a Leica fluorescence microscope.
Statistical analysis
Differences between groups were compared using the Student's t-test (two-sided analysis) using the Prism software program. All data shown were the mean7s.e.m. A P-value o0.05 was considered significant.
